Paul Hastings LLP advised Piper Sandler and Co. as lead placement agent, and Oppenheimer & Co. as placement agent in the transaction. Skye Bioscience, Inc. (OTCQB:...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised J.P. Morgan and Leerink Partners as co-lead placement agents, and Stifel co-placement agent, in the transaction. Lexeo Therapeutics, Inc. (Nasdaq: LXEO) has entered...
You must be a Standard 1 Year member to access this content.
Covington & Burling represented Humacyte, while Paul Hastings advised TD Cowen, Cantor and BTIG in the offering. Humacyte, Inc. executed an underwritten public offering of 13,400,000 shares...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Leerink Partners on the matter. PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised the lead placement agent and the placement agent. Skye Bioscience, Inc. (OTCQB: SKYE), a clinical stage biotechnology company focused on the discovery,...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Jefferies LLC as sole book running manager in connection with Esperion Therapeutics, Inc.’s offering. Esperion Therapeutics, Inc. announced the pricing of its...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised TD Cowen and the placement agents in connection with Harpoon Therapeutics’ offering. Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised the underwriters in connection with Lexeo Therapeutics’ IPO. Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to transforming...
You must be a Standard 1 Year member to access this content.
Cooley advised CymaBay, and Paul Hastings advised the representatives of the underwriters. CymaBay Therapeutics, Inc. announced its $258.75 million follow-on offering of common stock and pre-funded...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP announced that experienced capital markets lawyer Seo Salimi has joined the firm in New York as a partner, co-head of the equity capital...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP announced that experienced capital markets lawyer Seo Salimi has joined the firm in New York as a partner, co-head of the equity capital...
You must be a Standard 1 Year member to access this content.
Arnold & Porter advised Coherus Biosciences Inc. on the deal, and Goodwin advised Surface Oncology. Coherus Biosciences Inc. (Coherus) announced its acquisition of Surface Oncology Inc. (Surface),...
You must be a Standard 1 Year member to access this content.
